Cargando…

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML relapse thereby negatively impacting disease outcome. Over the last years myeloid derived sup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jitschin, Regina, Saul, Domenica, Braun, Martina, Tohumeken, Sehmus, Völkl, Simon, Kischel, Roman, Lutteropp, Michael, Dos Santos, Cedric, Mackensen, Andreas, Mougiakakos, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217777/ https://www.ncbi.nlm.nih.gov/pubmed/30396365 http://dx.doi.org/10.1186/s40425-018-0432-9

Ejemplares similares

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
por: Harrington, Kimberly H., et al.
Publicado: (2015)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
por: Baur, Rebecca, et al.
Publicado: (2021)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
por: Laszlo, G S, et al.
Publicado: (2015)

A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
por: Brey, Charlotte U., et al.
Publicado: (2018)

Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation: A double-edged sword?
por: Le Blanc, Katarina, et al.
Publicado: (2013)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity
por: Stoll, A., et al.
Publicado: (2021)

T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
por: Feucht, Judith, et al.
Publicado: (2016)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
por: Meckler, Joshua F., et al.
Publicado: (2023)

Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9(high) AML cell subset
por: Böttcher, Martin, et al.
Publicado: (2022)

FLT3‐ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
por: Soare, Dan‐Sebastian, et al.
Publicado: (2020)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
por: Allen, Cecily, et al.
Publicado: (2021)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
por: Kujawski, Maciej, et al.
Publicado: (2019)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
por: Cheng, Pingyan, et al.
Publicado: (2022)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome
por: Richter, Silja, et al.
Publicado: (2022)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
por: Hoffman, Lindsey M., et al.
Publicado: (2014)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

Role of CAR T Cell Metabolism for Therapeutic Efficacy
por: Rial Saborido, Judit, et al.
Publicado: (2022)

Repression of phagocytosis by human CD33 is not conserved with mouse CD33
por: Bhattacherjee, Abhishek, et al.
Publicado: (2019)

S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
por: Haubner, Sascha, et al.
Publicado: (2023)

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2021)

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
por: Kebenko, Maxim, et al.
Publicado: (2018)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML)
por: Jiang, Yongfang, et al.
Publicado: (2017)

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
por: Stanchina, Michele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_atnv9l5l26q5oteu7tl03v20b0